Combination treatment with nivolumab and cabozantinib provides long-term benefits over sunitinib in patients with advanced RCC, according to final results from the CheckMate 9ER trial.

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final ...

The primary endpoint was progression-free survival (PFS; nivolumab/ipilimumab vs chemotherapy and nivolumab/ipilimumab vs nivolumab monotherapy). Findings showed the risk of disease progression or ...

A comprehensive study of effective responses as well as resistant responses to a kidney cancer anti-PD-1 therapy found ...

Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of ...

THURSDAY, Feb. 6, 2025 (HealthDay News) -- For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC) ...

In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.